Refine your search
971 results found
Fenwick & West LLP | USA | 18 Nov 2021
2021 Proxy Season Results in Silicon Valley and at Large Companies Nationwide
Shareholder activism has been a significant phenomenon amongst the largest U.S. public companies, with activists of a variety of stripes waging…
Pearce IP | Australia | 8 Nov 2021
Pearce IP BioBlast®: w/e 05 November 2021
The International Generic and Biosimilar Medicines Association called on all stakeholders ahead of its second Global Biosimilars Week to…
Venable LLP | USA | 8 Nov 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection - October 2021
On October 15, 2021, the FDA approved Boehringer Ingelheim's Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie's Humira® (adalimumab)…
Venable LLP | USA | 25 Oct 2021
FDA Approves Boehringer Ingelheim’s Cyltezo® as Interchangeable with Humira®
On October 15, 2021, the FDA approved Boehringer Ingelheim’s Cyltezo® (adalimumab-adbm) as interchangeable with AbbVie’s Humira® (adalimumab) for…
Crowell & Moring LLP | USA | 25 Oct 2021
AbbVie Trade Secret Claims Fail at Pleading Stage for Lack of Jurisdiction
In March 2021, AbbVie, Inc. and AbbVie Biotechnology Ltd. (“AbbVie”) sued rival pharmaceutical company Alvotech hf. (“Alvotech”) for trade secret…
Pearce IP | Australia | 18 Oct 2021
Pearce IP BioBlast®: w/e 15 October 2021
Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking approval of regdanvimab for the treatment of…
Pearce IP | Australia | 11 Oct 2021
Pearce IP BioBlast®: w/e 08 October 2021
Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in combination with chemotherapy to treat specific types of…
Pearce IP | Australia | 5 Oct 2021
Pearce IP BioBlast®: w/e 01 October 2021
Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD $375 million with a further USD $50 million…
Pearce IP | Australia | 27 Sep 2021
Pearce IP BioBlast®: w/e 24 September 2021
Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a statistically significant and clinically…
Osler Hoskin & Harcourt LLP | Canada | 24 Sep 2021
The impact of CAR T cell patenting on access to therapy in Canada
Typically, when launching a new therapy, such as a drug or biologic, the sponsor of the therapy attempts to obtain broad patent protection to prevent…
